HCA HCA Healthcare, Inc.

XNYS 467.31 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

HCA $467.31 —
Key stats
$467.31
52-Week Range
$353.99 – $556.52
YTD
-0.65%
IV Rank (30D)
56.59
Straddle Price
$42.15
P/C Vol Ratio
1.21
Market Cap
$99.5B
Open
$460.89
Day Range
$456.18 – $467.31
Volume
872,801
Prev Close
$459.40
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.15%
Beta vs SPY0.83
Cost of Equity (CAPM)9.29% (VRP-adj)
WACC8.14%
Volatility Risk Premium+26.3pp (IV − HV30)
Effective Tax Rate20.4%
Rev. Growth (YoY, DCF input)+5.6%
DCF Horizon10 years explicit + fade
Forward Tilt (NTM/TTM)×1.06 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$6.0B
Return on Equity (TTM)-103.0%
Book / Price-3.0%
Gross Margin (TTM)100.0%
FCF Margin (TTM)7.7%
Quality Score2/6 — normal (10y DCF)
Market-Implied Growth+7.7% (reverse-DCF on current price)
SMA 50$429.31 (Market Anchor value)
SMA 20 / Bollinger Mid$444.98
Bollinger Width / SMA203.2% (drives anchor stability)
Net Debt$42.4B
Market Cap$106B
Peers used for multiples: ABBV, CI, ELV, GILD, JNJ, LLY, MRK, UNH
60-Day Conviction
76%
20-Day Fair Value
≈ by Nov 20, 2026
$478.95
α +2.5% rank 59%
conviction
95%
40-Day Fair Value
≈ by Dec 21, 2026
$485.70
α +3.9% rank 53%
conviction
94%
60-Day Fair Value
≈ by Jan 19, 2027
$479.26
α +2.6% rank 53%
conviction
76%
MethodImplied PriceWeightDetail
DCF $383.89 20%
DDM (Gordon) $74.92 0%
Peer P/E $935.69 5% median 29.7× · 7 peers
Peer EV/EBITDA $1213.57 6% median 19.4× · 8 peers
Peer P/B n/a 0% median 7.4× · 7 peers
Peer P/S $2113.54 8% median 5.9× · 8 peers
Market Anchor (SMA50) $429.31 41% stability 100% (BB-width)
Options Expected (B-L 30d) $463.21 20% 74 strikes · skew +0.57
As of 2026-10-22 · updated
About
Industry (SIC)
SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC (8062) · industry map
Exchange
XNYS
Market Cap
$99.5B
Employees
320,000
List Date
2011-03-10
CIK
0000860730
Next Earnings
2026-10-27 (Pre-Market)
EPS Forecast
$6.75 (9 est.)
Headquarters
Nashville, TN
Homepage
https://www.hcahealthcare.com

HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2025, the firm owned and operated 190 hospitals and over 2,500 outpatient facillities across 19 states and a small foothold in the United Kingdom.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan-0.71%-5.52%4.88%10.74%10.80%3.80%4.00%
Feb3.06%5.47%-6.89%-0.94%-8.38%6.61%-0.18%
Mar7.34%-0.71%7.93%6.91%11.01%-11.20%3.55%
Apr8.01%-14.44%8.77%-6.15%-0.19%-8.49%-2.08%
May5.03%-0.20%-6.98%9.80%11.18%-12.60%1.04%
Jun-4.23%-18.79%13.29%-3.43%0.25%5.10%-1.30%
Jul17.17%21.34%-8.32%15.21%-9.12%2.38%6.44%
Aug0.79%-6.18%1.25%8.94%13.16%1.93%3.31%
Sep-3.93%-7.85%-12.40%2.68%4.94%3.18%-2.23%
Oct1.08%12.53%-8.52%-11.52%7.89%10.37%*1.97%
Nov-10.12%8.63%11.15%-8.39%10.12%--2.28%
Dec13.88%0.62%7.26%-8.39%-7.18%--1.24%
Total40.08%-11.47%7.14%11.68%49.20%-1.84%15.80%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $447.18
SMA 50: $430.37
SMA 200: $444.67
Current: $467.31
EMA 12: $456.87
EMA 26: $446.09
MACD: 10.7831 | Signal: 0.9015
BULLISH
ADX (14): 29.01
TREND
+DI: 27.56
−DI: 14.24

Momentum Oscillators

RSI (14): 63.85
NEUTRAL
Stoch %K: 73.10
Stoch %D: 68.52
Williams %R: -21.85

Volume & Volatility

BB Upper: $478.34
BB Lower: $416.01
NEUTRAL
OBV: 16,363,901
Vol SMA 20: 1,079,499
Vol ROC: -22.58%
ATR: $11.72
True Range: $11.13
HV 20: 22.8%
HV 30: 23.3%
HV 60: 26.4%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-24T00:00:00 – 2026-10-22T00:00:00
AI Analysis

LLM Stock Analysis Report

SYMBOL: HCA CURRENT PRICE: $387.18

Executive Summary: Overall assessment: NEUTRAL (6/10) with confidence level moderate to low.

Key drivers:

  • The stock has been trading within a range, with no clear trend direction.
  • Technical indicators suggest the stock is in a neutral zone, with RSI indicating oversold conditions and MACD flashing a bearish signal.

Primary risks:

  • The stock's beta is low (0.20), indicating lower volatility than the market.
  • Historical volatility levels are relatively high, which may indicate increased risk for potential buyers.

Investment thesis: HCA Healthcare appears to be in a consolidation phase, with no clear directional momentum. The stock's low volatility and neutral technical indicators suggest it may continue trading within its current range, making it challenging to predict significant price movements.

Recent news sentiment impact: The recent news headlines have been mixed, with some articles highlighting the company's strong fundamentals (positive sentiment) while others mentioned soft admissions mix and respiratory season volumes lagging (negative sentiment). This mixed sentiment has not had a significant impact on the stock's technical indicators or trading range.

Technical Analysis:

  • Trend Direction: Neutral
  • Support/Resistance Levels: Key levels to monitor are $384.60 (SMA 20), $349.36 (Bollinger Bands Lower), and $419.85 (Bollinger Bands Upper).
  • Momentum Signals:
    • RSI interpretation: Oversold conditions, potential buy signal.
    • MACD signal: Bearish crossover, suggesting further consolidation or potential downside movement.
    • Bollinger Bands position: Neutral, indicating no strong momentum.
  • Volume Analysis: Volume trends suggest a neutral market environment, with no clear institutional interest signals.

News & Sentiment Analysis:

  • Recent Headlines Summary: Mixed news sentiment, with some articles highlighting the company's strong fundamentals and others mentioning soft respiratory season volumes.
  • Sentiment Assessment: Aggregate news sentiment is NEUTRAL (50/50).
  • Catalyst Identification: No imminent catalysts identified.

Risk & Volatility Assessment:

  • Beta Interpretation: Low volatility, indicating lower risk relative to the market (beta 0.20).
  • Volatility Regime: Current volatility levels are relatively high compared to historical averages.
  • Options Market Signals: IV rank is medium-high (39.6%), suggesting some level of volatility. The options market is pricing a $29.15 move by expiration, indicating some level of risk.

Market Context & Positioning:

  • Sector Performance: HCA Healthcare's performance has been in line with the healthcare sector.
  • Institutional Activity: No clear institutional interest signals are present.
  • Correlation Analysis: The stock moves less than the market (0.09), indicating a relatively low correlation.

Key Levels & Action Items:

  • Critical Price Levels: $384.60 (SMA 20), $349.36 (Bollinger Bands Lower), and $419.85 (Bollinger Bands Upper).
  • Breakout/Breakdown Levels: No clear breakout or breakdown levels identified.
  • Time-Sensitive Catalysts: No imminent earnings dates, FDA approvals, or product launches are scheduled.
  • Risk Management: Consider stop-loss levels at $384.60 and position sizing considerations based on the stock's volatility.

Note: This report focuses on risk-reward analysis only and does not provide buy/sell recommendations. The provided data should be used as a reference for further research and analysis.

Generated
News
All HCA news →
Earnings History
19 of 23 under expected move
Avg Expected Move
7.22%
Avg Actual Move
5.37%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-02-02 Pre-Market 5.04% 0.65% 0.13x Within
2021-04-22 Pre-Market 3.95% 2.01% 0.51x Within
2021-07-20 Pre-Market 4.20% 14.37% 3.42x Exceeded
2021-10-22 Pre-Market 4.40% 2.65% 0.60x Within
2022-01-27 Pre-Market 5.12% 4.65% 0.91x Within
2022-04-22 Pre-Market 4.82% 21.82% 4.53x Exceeded
2022-07-22 Pre-Market 10.09% 11.43% 1.13x Exceeded
2022-10-21 Pre-Market 8.36% 5.73% 0.69x Within
2023-01-27 Pre-Market 9.22% 0.03% 0.00x Within
2023-04-21 Pre-Market 5.30% 3.85% 0.73x Within
2023-07-27 Pre-Market 6.31% 2.08% 0.33x Within
2023-10-24 Pre-Market 8.18% 4.49% 0.55x Within
2024-01-30 Pre-Market 6.80% 5.18% 0.76x Within
2024-04-26 Pre-Market 7.23% 2.37% 0.33x Within
2024-07-23 Pre-Market 8.19% 4.55% 0.56x Within
2024-10-25 Pre-Market 9.29% 8.86% 0.95x Within
2025-01-24 Pre-Market 8.16% 3.78% 0.46x Within
2025-04-25 Pre-Market 8.87% 3.95% 0.45x Within
2025-07-25 Pre-Market 9.47% 2.10% 0.22x Within
2025-10-24 Pre-Market 7.25% 1.56% 0.22x Within
2026-01-27 Pre-Market 8.05% 7.08% 0.88x Within
2026-04-24 Pre-Market 8.12% 8.77% 1.08x Exceeded
2026-07-24 Pre-Market 9.61% 1.51% 0.16x Within

Earnings calendar: this week’s reports with expected vs actual moves →

HCA Options Activity & IV Rank

HCA IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 39.1%
7-DTE IV: —
Expected Move: $42.15
7-DTE Move: $42.15
Days to Exp: 29 (2026-11-20)

Options Flow

Call Volume: 270
Put Volume: 326
P/C Volume: 1.207
NEUTRAL
Call OI: 3,256
Put OI: 6,145
P/C OI: 1.887
Total OI: 9,401

ATM Options Pricing

ATM Call: $22.25
ATM Put: $19.90
Call %: 4.8%
Put %: 4.3%

Chain Summary

Chain Volume: 4,180
Chain OI: 32,233
Last Updated: 10/22/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 44th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
44%
vs own history
GEX tilt
+0.10
OI-weighted, today
Vanna tilt
+0.60
δ-sensitivity to IV
Charm tilt
-0.70
δ-decay vs time
Vanna tilt +0.60: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.70: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 100 ATM contracts, 15k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 22 · No data
30 DTE / 10d 32%
+3.8 pts EXTREME
as of Oct 22 · ATM 40.1% / Wing 43.8%

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)56.6MediumOct 22
Straddle Price (30 DTE)$42.15Oct 22
Beta Analysis

Risk Metrics

Beta: 0.1627
Alpha: 8.29%
Correlation: 0.0665
R-Squared: 0.4%
Stock Volatility: 31.2%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time

HCA Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 231,289,000 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

1,396 filers147,406,047 shares$58.83B value63.73% of float
# Filer Shares Value % of Total % of Float Period
1 Vanguard Group Inc Custodian 14,716,173 $6.87B 11.68% 6.36% 2025-12-31
2 BlackRock, Inc. Custodian 13,003,600 $5.07B 8.62% 5.62% 2026-06-30
3 Vanguard Capital Management LLC 10,141,708 $3.95B 6.72% 4.38% 2026-06-30
4 Sanders Capital, LLC 8,828,287 $3.44B 5.85% 3.82% 2026-06-30
5 State Street Corp 7,469,035 $2.91B 4.95% 3.23% 2026-06-30
6 Wellington Management Group LLP Custodian 4,707,473 $1.84B 3.12% 2.04% 2026-06-30
7 Geode Capital Management, LLC Custodian 3,668,008 $1.42B 2.42% 1.59% 2026-06-30
8 First Eagle Investment Management, LLC 3,295,565 $1.28B 2.18% 1.42% 2026-06-30
9 Vanguard Portfolio Management LLC 2,712,828 $1.06B 1.80% 1.17% 2026-06-30
10 Morgan Stanley Custodian 2,586,771 $1.01B 1.71% 1.12% 2026-06-30
11 Goldman Sachs Group Inc Custodian 2,464,314 $960.81M 1.63% 1.07% 2026-06-30
12 JPMorgan Chase & Co Custodian 2,285,832 $896.80M 1.52% 0.99% 2026-06-30
13 Arrowstreet Capital, Limited Partnership 2,209,485 $861.46M 1.46% 0.96% 2026-06-30
14 Norges Bank 2,145,367 $836.46M 1.42% 0.93% 2026-06-30
15 Capital World Investors 1,977,121 $770.86M 1.31% 0.85% 2026-06-30
16 Capital International Investors 1,916,947 $747.40M 1.27% 0.83% 2026-06-30
17 Northern Trust Corp Custodian 1,708,560 $666.15M 1.13% 0.74% 2026-06-30
18 FMR LLC Custodian 1,632,520 $636.50M 1.08% 0.71% 2026-06-30
19 Invesco Ltd. Custodian 1,529,637 $596.39M 1.01% 0.66% 2026-06-30
20 Nordea Investment Management AB 1,429,943 $553.70M 0.94% 0.62% 2026-06-30
21 Barclays PLC Custodian 1,319,216 $514.35M 0.87% 0.57% 2026-06-30
22 UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Custodian 1,244,576 $485.25M 0.82% 0.54% 2026-06-30
23 Janus Henderson Group plc 1,017,441 $481.49M 0.82% 0.44% 2026-03-31
24 Crake Asset Management LLP 1,151,792 $449.07M 0.76% 0.50% 2026-06-30
25 Metropolis Capital Ltd 910,564 $430.92M 0.73% 0.39% 2026-06-30
34 filers$708.25M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $151.47M 21.39% 2026-06-30
2 Jane Street Group, LLC Custodian $119.54M 16.88% 2026-06-30
3 Citadel Advisors LLC Custodian $105.66M 14.92% 2026-06-30
4 IMC-Chicago, LLC Custodian $78.68M 11.11% 2026-06-30
5 Wolverine Trading, LLC Custodian $42.60M 6.01% 2025-09-30
6 Squarepoint Ops LLC $39.57M 5.59% 2026-06-30
7 GROUP ONE TRADING LLC Custodian $24.13M 3.41% 2026-06-30
8 Citigroup Inc. Custodian $19.07M 2.69% 2026-06-30
9 Point72 Asset Management, L.P. $12.52M 1.77% 2026-06-30
10 UBS Group AG Custodian $12.40M 1.75% 2026-06-30
11 TUDOR INVESTMENT CORP ET AL $11.15M 1.57% 2026-06-30
12 Cubist Systematic Strategies, LLC $9.67M 1.37% 2025-09-30
13 SIG BROKERAGE, LP $8.77M 1.24% 2026-06-30
14 Walleye Trading LLC $8.15M 1.15% 2026-06-30
15 Millennium Management LLC Custodian $7.76M 1.10% 2026-06-30
16 D. E. Shaw & Co., Inc. Custodian $7.21M 1.02% 2026-06-30
17 BNP Paribas Financial Markets Custodian $7.10M 1.00% 2026-06-30
18 NOMURA HOLDINGS INC $6.08M 0.86% 2026-06-30
19 CAPITAL FUND MANAGEMENT S.A. $5.65M 0.80% 2026-06-30
20 Simplex Trading, LLC Custodian $5.65M 0.80% 2026-06-30
21 Balyasny Asset Management L.P. $4.56M 0.64% 2026-06-30
22 Walleye Capital LLC $4.44M 0.63% 2026-06-30
23 Allianz Asset Management GmbH $4.37M 0.62% 2026-06-30
24 Qube Research & Technologies Ltd $3.00M 0.42% 2026-06-30
25 CAPSTONE INVESTMENT ADVISORS, LLC $1.99M 0.28% 2026-06-30
37 filers$400.19M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $92.25M 23.05% 2026-06-30
2 Citadel Advisors LLC Custodian $57.24M 14.30% 2026-06-30
3 Jane Street Group, LLC Custodian $42.11M 10.52% 2026-06-30
4 IMC-Chicago, LLC Custodian $34.43M 8.60% 2026-06-30
5 Millennium Management LLC Custodian $31.50M 7.87% 2026-06-30
6 Wolverine Trading, LLC Custodian $23.82M 5.95% 2025-09-30
7 UBS Group AG Custodian $14.00M 3.50% 2026-06-30
8 Pentwater Capital Management LP $13.65M 3.41% 2026-06-30
9 GROUP ONE TRADING LLC Custodian $10.80M 2.70% 2026-06-30
10 BNP Paribas Financial Markets Custodian $8.69M 2.17% 2026-06-30
11 Militia Capital Management LLC $8.50M 2.12% 2026-06-30
12 Squarepoint Ops LLC $8.19M 2.05% 2026-06-30
13 NOMURA HOLDINGS INC $5.03M 1.26% 2026-06-30
14 Allianz Asset Management GmbH $4.91M 1.23% 2026-06-30
15 Point72 Asset Management, L.P. $4.48M 1.12% 2026-06-30
16 CAPTRUST FINANCIAL ADVISORS $4.21M 1.05% 2026-06-30
17 JPMorgan Chase & Co Custodian $4.04M 1.01% 2026-06-30
18 CREDIT AGRICOLE S A $3.90M 0.97% 2026-06-30
19 Simplex Trading, LLC Custodian $3.78M 0.94% 2026-06-30
20 Cubist Systematic Strategies, LLC $3.75M 0.94% 2025-09-30
21 Qube Research & Technologies Ltd $3.08M 0.77% 2026-06-30
22 TUDOR INVESTMENT CORP ET AL $3.00M 0.75% 2026-06-30
23 Per Stirling Capital Management, LLC. $2.61M 0.65% 2026-06-30
24 CAPSTONE INVESTMENT ADVISORS, LLC $2.46M 0.61% 2026-06-30
25 D. E. Shaw & Co., Inc. Custodian $2.03M 0.51% 2026-06-30

HCA Insider Trading (Form 4)

Latest: 2026-08-28
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-28 Michael R McAlevey EVP & Chief Legal & Admin Off. Other (J) −7,769 $429.00 -$3.33M EDGAR
2026-05-11 Mike A Marks EVP and CFO Gift (G) — — EDGAR
2026-04-30 John Chidsey Director Award (A) +809 — EDGAR
2026-04-30 Nancy Ann Deparle Director Award (A) +509 — EDGAR
2026-04-30 Hugh F Johnston Director Award (A) +809 — EDGAR
2026-04-30 Michael W Michelson Director Award (A) +925 — EDGAR
2026-04-30 Wayne Joseph Riley Director Award (A) +509 — EDGAR
2026-04-30 Andrea B Smith Director Award (A) +509 — EDGAR
2026-04-30 Thomas F Frist III Director Award (A) +1,041 — EDGAR
2026-04-30 William R Frist Director Award (A) +809 — EDGAR
2026-02-18 Michael R McAlevey EVP & Chief Legal & Admin Off. Mixed — $387.28 -$1.51M EDGAR
2026-02-12 Jennifer Berres SVP & Chief Human Res. Officer Mixed −3,419 $511.59 -$5.39M EDGAR
2026-02-12 Michael S. Cuffe EVP and Chief Clinical Officer Mixed +6,127 $502.05 -$1.76M EDGAR
2026-02-12 Jon M Foster EVP and COO Mixed +9,808 $502.05 -$2.96M EDGAR
2026-02-12 Samuel N Hazen CEO Mixed +33,611 $502.05 -$10.71M EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

HCA Insider Holdings

24 insiders · @ $467.31
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Patricia F Elcan 10%+ Owner 32,323,941 $15.11B $95.6K 4 2026-02-10
2 HERCULES HOLDING II 10%+ Owner 32,282,889 $15.09B -$6.34B 23 2026-02-10
3 Thomas F Frist Jr 10%+ Owner 478,955 $223.82M $52.98M 5 2026-02-10
4 Samuel N Hazen CEO 81,573 $38.12M -$89.05M 52 2026-02-12
5 Erol R Akdamar Group President 80,000 $37.38M -$2.80M 10 2024-11-14
6 Phillip G Billington SVP-Internal Audit Services 52,702 $24.63M -$5.25M 16 2024-11-14
7 Christopher F. Wyatt SVP & Controller 48,379 $22.61M -$9.57M 33 2026-02-12
8 Mike A Marks EVP and CFO 46,576 $21.77M $0 14 2026-05-11
9 Jon M Foster EVP and COO 40,516 $18.93M -$51.08M 63 2026-02-12
10 Michael S. Cuffe EVP and Chief Clinical Officer 35,580 $16.63M -$31.92M 70 2026-02-12
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

HCA Board & Officers

As of SEC filings through Sep 11, 2026

Directors 9

Officers 9

10% owners 6

Changes in the last 10 years (41)
Sep 1, 2026Michael J Schlosser became EVP and Chief Clinical Officer
Feb 20, 2026The company announced the departure of Robert J Dennis from the board in an SEC filing
Feb 1, 2026Erica Rossitto became SVP & Chief Nurse Executive
Jul 15, 2025John Chidsey became a director
Feb 19, 2025The company announced the departure of Meg Crofton from the board in an SEC filing
May 1, 2024Mike A Marks listed as EVP and CFO (previously SVP-Finance) in SEC filings
May 1, 2024Michael R McAlevey listed as EVP & Chief Legal & Admin Off. (previously SVP & Chief Legal Officer) in SEC filings
Feb 1, 2024Chad J Wasserman became SVP and CIO
Jan 24, 2024The company announced the departure of Bill B Rutherford as CFO and EVP in an SEC filing
Feb 1, 2023Jon M Foster listed as EVP and COO (previously Group President) in SEC filings
Jan 1, 2023Timothy M McManus became Group President
Jan 1, 2023Richard A Hammett became Group President
Jan 1, 2023Mike A Marks became SVP-Finance
Jan 1, 2023Erol R Akdamar became Group President
Aug 15, 2022The company announced the departure of Charles J Hall as Group President in an SEC filing
Feb 14, 2022Robert A Waterman reported in an SEC filing no longer being SVP & General Counsel
Feb 14, 2022J William Morrow reported in an SEC filing no longer being SVP - Finance and Treasurer
Feb 1, 2022Michael S. Cuffe listed as EVP and Chief Clinical Officer (previously President-Physician Services) in SEC filings
Jan 26, 2022Andrea B Smith became a director
Jan 24, 2022Michael R McAlevey became SVP & Chief Legal Officer
Not reported recently (29)
  • Sammie S Mosier · Last reported as SVP & Chief Nurse Executive in an SEC filing dated Feb 18, 2025
  • Kathleen M Whalen · Last reported as SVP & Chief Ethics Officer in an SEC filing dated Nov 18, 2024
  • Phillip G Billington · Last reported as SVP-Internal Audit Services in an SEC filing dated Nov 14, 2024
  • Erol R Akdamar · Last reported as Group President in an SEC filing dated Nov 14, 2024
  • Joseph A Sowell III · Last reported as SVP; Chief Development Officer in an SEC filing dated Aug 7, 2024
  • Timothy M McManus · Last reported as Group President in an SEC filing dated Aug 2, 2024
  • Deborah M Reiner · Last reported as SVP - Mktg. & Communications in an SEC filing dated Jul 31, 2024
  • Kathryn A. Torres · Last reported as SVP-Payer Contracting & Align. in an SEC filing dated Jul 29, 2024
  • Jeffrey E. Cohen · Last reported as SVP-Government Relations in an SEC filing dated May 13, 2024
  • Chad J Wasserman · Last reported as SVP and CIO in an SEC filing dated Mar 20, 2024
  • Richard A Hammett · Last reported as Group President in an SEC filing dated Feb 21, 2024
  • P. Martin Paslick · Last reported as SVP and CIO in an SEC filing dated Apr 14, 2023
  • A Bruce Moore Jr · Last reported as Group President - Service Line in an SEC filing dated Nov 15, 2022
  • Charles O Holliday Jr · Last reported as a director in an SEC filing dated Apr 27, 2022
  • Jane D. Englebright · Last reported as SVP and Chief Nursing Officer in an SEC filing dated Nov 12, 2021
  • Jonathan B Perlin · Last reported as Pres-Clinical Operations & CMO in an SEC filing dated Aug 4, 2021
  • Sandra L. Morgan · Last reported as SVP-Provider Relations in an SEC filing dated Feb 22, 2021
  • Victor L Campbell · Last reported as SVP-Government Affairs in an SEC filing dated May 3, 2019
  • Geoffrey G Meyers · Last reported as a director in an SEC filing dated May 3, 2019
  • John W Rowe · Last reported as a director in an SEC filing dated May 3, 2019
  • John M Steele · Last reported as SVP & Chief Human Res. Officer in an SEC filing dated Feb 27, 2019
  • R Milton Johnson · Last reported as a director in an SEC filing dated Feb 27, 2019
  • Ann H Lamont · Last reported as a director in an SEC filing dated May 4, 2018
  • Alan R Yuspeh · Last reported as SVP & Chief Ethics Officer in an SEC filing dated Feb 26, 2018
  • Joseph N Steakley · Last reported as SVP-Internal Audit Services in an SEC filing dated Feb 26, 2018
  • Ravi S. Chari · Last reported as SVP-Clinical Excellence in an SEC filing dated Feb 26, 2018
  • Jana Joustra Davis · Last reported as SVP - Mktg. & Corp. Affairs in an SEC filing dated May 25, 2017
  • Jay O Light · Last reported as a director in an SEC filing dated May 5, 2017
  • David Gwin Anderson · Last reported as SVP - Finance in an SEC filing dated Nov 9, 2016
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

HCA Proposed Insider Sales (Form 144)

Latest: 2026-02-18
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-02-18 Michael R McAlevey OFFICER 1,694 $903.5K 2026-02-18 Merrill Lynch — EDGAR
2026-02-11 Jennifer L. Berres OFFICER 8,020 $4.13M 2026-02-11 Merrill Lynch — EDGAR
2026-02-03 MICHAEL S CUFFE OFFICER 1,500 $747.1K 2026-02-03 Merrill Lynch — EDGAR
2026-02-03 Samuel N. Hazen President, Chief Executive Officer & Director 42,877 $21.48M 2026-02-03 Merrill Lynch — EDGAR
2025-11-05 Michael R McAlevey OFFICER 3,892 $1.84M 2025-11-05 Merrill Lynch — EDGAR
2025-09-08 Cuffe Michael S. Officer 3,836 $1.61M 2025-09-08 MERRILL LYNCH 10b5-1 EDGAR
2025-05-13 Foster Jon M Officer 15,698 $5.80M 2025-05-13 Merrill Lynch — EDGAR
2025-02-14 Berres Jennifer Officer 9,533 $3.08M 2025-02-14 Merrill Lynch — EDGAR
2025-02-11 Reiner Deborah M Former Officer 3,510 $1.13M 2025-02-11 Merrill Lynch — EDGAR
2025-01-31 Whalen Kathleen M Former Officer 3,228 $1.08M 2025-01-31 Merrill Lynch — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-04-30
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Accession Link
2026-04-30 0001193125-26-197278 EDGAR
2026-04-28 0001193125-26-187155 EDGAR
2026-04-27 0001193125-26-182265 EDGAR
2026-04-24 0001193125-26-174933 EDGAR
2026-02-25 0001193125-26-071880 EDGAR
2026-01-27 0001193125-26-023323 EDGAR
2025-10-31 0001193125-25-260809 EDGAR
2025-10-27 0001193125-25-251612 EDGAR
2025-10-24 0001193125-25-249345 EDGAR
2025-07-25 0000950170-25-098578 EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-10 0001193125-26-044769 EDGAR
2025-02-14 0000950170-25-020134 EDGAR
2024-02-16 0000950170-24-016524 EDGAR
2023-02-17 0000950170-23-003234 EDGAR
2022-02-18 0001193125-22-046707 EDGAR
2021-02-19 0001193125-21-048994 EDGAR
2020-02-20 0001193125-20-043524 EDGAR
2019-02-21 0001193125-19-047078 EDGAR
2018-02-23 0001193125-18-056057 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-04-29 0001193125-26-191444 EDGAR
2025-10-30 0001193125-25-258667 EDGAR
2025-08-04 0000950170-25-102056 EDGAR
2025-05-01 0000950170-25-061895 EDGAR
2024-10-31 0000950170-24-119581 EDGAR
2024-07-29 0000950170-24-087322 EDGAR
2024-05-02 0000950170-24-052195 EDGAR
2023-10-26 0000950170-23-055641 EDGAR
2023-08-02 0000950170-23-037237 EDGAR
2023-04-27 0000950170-23-015314 EDGAR
ETF Holders
316 ETFs hold HCA
25 shown · $8.42B total exposure · 0.14% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.08% $1.9B — 2026-09-30
2 VOO Vanguard S&P 500 ETF Vanguard 0.10% $1.6B — 2026-09-30
3 IVV iShares Core S&P 500 ETF iShares (BlackRock) 0.10% $897.8M $878.4B 2026-10-21
4 SPY State Street® SPDR® S&P 500® ETF Trust SPDR (State Street) 0.10% $829.8M $820.7B 2026-10-21
5 VTV Vanguard Morningstar Value ETF Vanguard 0.23% $572.1M — 2026-09-30
6 XLV State Street® Health Care Select Sector SPDR® ETF SPDR (State Street) 1.04% $494.3M $47.5B 2026-10-21
7 COWZ Pacer US Cash Cows 100 ETF Nport 1.64% $299.0M — 2026-04-30
8 RSP Invesco S&P 500 Equal Weight ETF Invesco 0.22% $213.8M — 2026-10-21
9 VHT Vanguard Health Care ETF Vanguard 0.93% $202.5M — 2026-09-30
10 SPYM State Street® SPDR® Portfolio S&P 500® ETF SPDR (State Street) 0.10% $186.6M $184.5B 2026-10-21
11 IWD iShares Russell 1000 Value ETF iShares (BlackRock) 0.18% $149.7M $84.8B 2026-10-21
12 IVW iShares S&P 500 Growth ETF iShares (BlackRock) 0.18% $143.9M $75.8B 2026-10-21
13 SPYG State Street® SPDR® Portfolio S&P 500® Growth ETF SPDR (State Street) 0.18% $104.4M $56.4B 2026-10-21
14 CGGR Capital Group Growth ETF Capitalgroup 0.38% $100.3M $26.2B 2026-10-21
15 ITOT iShares Core S&P Total U.S. Stock Market ETF iShares (BlackRock) 0.09% $87.6M $96.2B 2026-10-21
16 VV Vanguard Morningstar Large-Cap ETF Vanguard 0.09% $70.7M — 2026-09-30
17 DYNF iShares U.S. Equity Factor Rotation Active ETF iShares (BlackRock) 0.15% $64.3M $42.1B 2026-10-21
18 IHF iShares U.S. Healthcare Providers ETF iShares (BlackRock) 4.63% $64.1M $1.4B 2026-10-21
19 SCHX Schwab U.S. Large-Cap ETF Nport 0.09% $63.1M — 2026-05-31
20 IUSG iShares Core S&P U.S. Growth ETF iShares (BlackRock) 0.18% $59.7M $33.0B 2026-10-21
21 VT Vanguard Total World Stock ETF Vanguard 0.05% $54.1M — 2026-09-30
22 JPEF JPMorgan Equity Focus ETF JPMorgan 2.59% $53.0M $2.0B 2026-10-22
23 JAVA JPMorgan Active Value ETF JPMorgan 0.71% $52.0M $7.4B 2026-10-21
24 DGRO iShares Core Dividend Growth ETF iShares (BlackRock) 0.12% $51.1M $44.8B 2026-10-21
25 VOOG Vanguard S&P 500 Growth ETF Vanguard 0.17% $47.5M — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
15.67
TTM Diluted EPS
$29.83
TTM Revenue
$78.01B
TTM Net Income
$6.84B
TTM Op. Cash Flow
$11.12B
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30$20.23B$1.70B$7.62$2.33B
Q1 '262026-03-31$19.11B$1.62B$7.15$2.01B
Q4 '252025-12-31$19.51B$1.88B$8.10$2.36B
Q3 '252025-09-30$19.16B$1.64B$6.96$4.42B
Q2 '252025-06-30$18.61B$1.65B$6.83$4.21B
Q1 '252025-03-31$18.32B$1.61B$6.45$1.65B
Q4 '242024-12-31$18.29B$1.44B$5.63$2.56B
Q3 '242024-09-30$17.49B$1.27B$4.88$3.52B
Q2 '242024-06-30$17.49B$1.46B$5.53$1.97B
Q1 '242024-03-31$17.34B$1.59B$5.93$2.47B
Q4 '232023-12-31$17.30B$1.61B$5.90$2.67B
Q3 '232023-09-30$16.21B$1.08B$3.91$2.48B
Q2 2026 • period ending 2026-06-30 • filed 2026-07-28
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
15.67
P/B
—
P/S
1.39
EV/EBITDA
9.54
EV/Sales
1.93
ROE
—
ROA
10.8%
Div Yield
0.69%
FCF Yield
10.29%
Debt/Equity
—
Current Ratio
—
Market Cap
$108.08B
as of 2026-10-22
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
4.88M
SI % of Float
2.77%
Days to Cover
3.06
Short Vol Ratio
50.4%
Free Float
176.08M
Float %
81.3%
Short interest 2026-09-30 • Short volume 2026-10-22 • Float 2026-08-07